GVR Report cover Biopharmaceutical CMO And CRO Market Size, Share & Trends Report

Biopharmaceutical CMO And CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, And Segment Forecasts, 2021 - 2028

  • Published Date: Jan, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-1-68038-500-7
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 240

Report Overview

The global biopharmaceutical CMO and CRO market size was valued at 27.20 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.6% from 2021 to 2028. Rising investment in the biopharmaceutical industry by the prominent participants to enhance their productivity and efficiency has driven the bio-manufacturers to increase their focus on outsourcing activities. Currently, biopharma companies have begun outsourcing the resource and capital-intensive steps and, in few cases, the entire chain of biomanufacturing, thereby boosting demand for contract-based services. The coronavirus pandemic has resulted in disruptions in the supply chain of the overall pharmaceutical industry. However, the biopharmaceutical CMO and CRO have responded well to the outbreak as such organizations are the beneficiaries of supply chain disruptions. The CMOs and CROs based in the western hemisphere would especially benefit during the pandemic. For instance, the Australian government partnered with Sandoz and plans to provide an investment of around €50 million in order to spur the production of integrated antibiotics in Europe.

India biopharmaceutical CMO & CRO market size, by service type, 2016 - 2028 (USD Million)

Mergers and acquisitions help CMOs offer integrated bioprocessing services to their clients, which, in turn, makes CMOs/CROs an attractive and feasible option for the rapid product launch. In recent years, the biopharmaceutical industry has witnessed a significant number of consolidations. These consolidations were mainly aimed at business expansion and to stay competitive in the biopharmaceutical contract manufacturing and services market.

Although the biopharmaceutical CMO & CRO industry itself is relatively developed, the inception of new bioprocessing tools, novel therapeutics, and the priority shifts in the bio/pharmaceutical industry pertaining to products have resulted in an increase in the pressure on the contract bio-manufacturers. As a result, CDMOs are adopting different business models for addressing the needs of their clients and stakeholders in the best possible way.

Furthermore, the integration of single-use systems in production facilities helps the CMOs to economically expand the manufacturing capacity. The single-use products offer fast turnaround and limit allied activities, such as cleaning and changeover validation.

COVID19 impact: 1,069 new deals (excluding M&A) registered in Q2 2019, a decrease of 3% from 1,103 in Q2 2018

Pandemic Impact

Post COVID Outlook

Total disclosed biopharma licensing exhibited strong growth in worldwide spend during the second quarter of 2019, driving a 46% increase from $22.8 billion to $33.5 billion over the same time period in 2018

65% of biotherapeutics facilities make use of Contract Development and Manufacturing Organization (CDMO) services for at least some of their bioprocessing, and this is projected to significantly increase due to the pandemic

1,069 new deals (excluding mergers & acquisitions) were registered in Q2 2019, a decrease of 3% from 1,103 in Q2 2018

The CMO industry will continue to benefit from the crisis - short and long-term - as pharma & biotech companies engage in the ongoing search for agile, reliable, and competent partners

CMOs and CROs continued to garner high interest and accounted for 32% of biopharma deals during 2019

 In the next few years, players plan to focus their strategic initiatives to enhance agility, flexibility in order to adapt to these changing market environments


However, the contract negotiations between CMOs and customers are observed to be difficult owing to the regulatory landscape and complexity of service. Clients and CMOs are facing issues pertaining to the IP rights, warranty and liabilities, and prices and timelines, which increases the complexity of negotiations.

Source Insights

The mammalian segment held the largest share of 54.01% in 2020. Mammalian cell lines are estimated to be the dominant production systems for the manufacturing of large molecules. This is attributed to their capabilities to add human-like post-translational modifications to complex protein therapeutics.

Furthermore, the segment is greatly benefited from the introduction of novel, robust, and enhanced expression systems, improved process monitoring solutions, cell line engineering tools, automated screening methods, and disposable devices. These developments have led to the more productive and efficient manufacturing of biologics using mammalian cells.

Non-mammalian cell lines such as microbial cell lines are recognized as potent factories. Innovative strategies are being implemented to identify and explore the potential of various microbes. This, in turn, is anticipated to contribute to the lucrative growth of the non-mammalian biopharmaceutical manufacturing segment.

Service Type Insights

The contract manufacturing segment held the largest share of 57.7% in 2020. Currently, there are several entities in the marketplace that offer a wide range of services for biopharmaceutical manufacturing. The services range from research and discovery of candidates to the final market launch of the product.

A substantial number of CMOs and opportunistic CMOs present in the space are engaged in providing biopharma entities with plenty of services, including end-to-end coverage from cell cultivation to fill/finish services. Furthermore, clients are investing significantly to outsource the manufacturing aspect of their product development program. These factors have resulted in the largest share of this segment.

CROs are striving to capitalize on the potential avenues in the biopharmaceutical industry. The new market entrants and small participants that are focused on the development of biopharmaceuticals are anticipated to opt for the contract research services for their discovery programs of new candidates, thereby boosting the growth of contract research organizations.

Product Insights

The biologics segment held the largest share of 81.83% in 2020. Contract services are becoming an increasingly common cost-saving strategy for effective and reproducible manufacturing of large molecules, including biologics and biosimilars. With the growing popularity of biological therapeutics for patient care, several conventional drug manufacturers are seeking opportunities to enter the biologics market.

The high specificity of biologics, complex manufacturing steps, and a higher success rate when compared with other drug molecules have resulted in the dominance of this segment. The use of single-use bioreactors, continuous purification processing, disposable plastic containers, and real-time quality analysis has enabled the CMOs to meet the increasing service demand for biologics production effectively.

Global biopharmaceutical CMO & CRO market size, by product, 2020 (%)

Furthermore, several companies are investing in the development of biosimilars with an aim to outperform the safety, efficacy, disposition, or cost of earlier in-class innovator drugs. This has increased the level of competition amongst innovator manufacturers, which, in turn, is likely to benefit the CMOs.

Regional Insights

North America held the largest share of 33.85% in 2020. A significant number of approved products in the U.S. are being manufactured by CMOs. Several small and mid-size biopharmaceutical entities (SMEs) lack the resources and budget to establish facilities with well-equipped resources. This, in turn, has increased an inter-dependency between CMOs and SMEs in the U.S., resulting in the dominance of the U.S. market.

The Asia Pacific is expected to witness significant growth during the forecast period. The key reason for the rise in outsourcing in Asian countries includes cost-associated benefits, such as lower labor costs and operating costs, across the region. India is anticipated to witness significant progress owing to the high volume of large molecule production in this country.

The lack of global regulatory symmetry for biosimilar approval has significantly driven the Indian market. As of 2016, there were 50 approved biosimilars in India, out of which only 24 were approved in Europe and 5 in the U.S.

Key Companies & Market Share Insights

This market is fragmented in nature due to the presence of a substantial number of developed as well as medium to small-sized CMOs and CROs. Several market participants are privately held or are a part of private equity firms’ portfolios.

Some key CMOs in the space are Lonza; Rentschler Biotechnologie GmbH; Boehringer Ingelheim GmbH; JRS Pharma (Celonic GmbH); Inno Biologics Sdn Bhd; ProBioGen; BIOMEVA GmbH; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Samsung BioLogics; TOYOBO CO., LTD.; CMC Biologics; Patheon; AbbVie Inc.; Binex Co., Ltd.; and WuXi Biologics.

The CMOs are integrating automation and innovative technologies at their plants in order to improve their capabilities in terms of project throughput and product quality. This has driven the interest of large molecule manufacturers in the CMOs to meet the growing demand for biologics. Charles River Laboratories International, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; LabCorp; and Parexel International Corporation are engaged in offering contract research services for large molecule production. Some prominent players in the global biopharmaceutical CMO and CRO market include:

  • Boehringer Ingelheim GmbH

  • Lonza

  • Inno Biologics Sdn Bhd

  • Rentschler Biotechnologie GmbH



  • ProBioGen

  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.


  • Samsung BioLogics

Biopharmaceutical CMO & CRO Market Report Scope

Report Attribute


Market size value in 2021

USD 29.41 billion

Revenue forecast in 2028

USD 49.26 billion

Growth Rate

CAGR of 7.6% from 2021 to 2028

Base year for estimation


Historical data

2016 – 2019

Forecast period

2021 – 2028

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Source, service type, product, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; France; China; India; Brazil; South Africa

Key companies profiled

Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS PHARMA; BIOMEVA GmbH; ProBioGen; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; TOYOBO CO., LTD.; Samsung BioLogics

Customization scope

Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global biopharmaceutical CMO and CRO market report on the basis of source, service type, product, and region:

  • Source Outlook (Revenue, USD Million, 2016 - 2028)

    • Mammalian

    • Non-mammalian

  • Service Type Outlook (Revenue, USD Million, 2016 - 2028)

    • Contract Manufacturing

      • Process Development

        • Downstream

        • Upstream

      • Fill & Finish Operations

      • Analytical & QC studies

      • Packaging

    • Contract Research

      • Oncology

      • Inflammation & Immunology

      • Cardiology

      • Neuroscience

      • Others

  • Product Outlook (Revenue, USD Million, 2016 - 2028)

    • Biologics

      • Monoclonal antibodies (MABs)

      • Recombinant Proteins

      • Vaccines

      • Antisense, RNAi, & Molecular Therapy

      • Others

    • Biosimilars

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

    • Asia Pacific

      • China

      • India

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.